Infertility Drugs Market Report Scope & Overview:

The Infertility Drugs Market was valued at USD 4.22 Billion in 2025 and is expected to reach USD 7.58 Billion by 2035, growing at a CAGR of 6.03% from 2026–2035.

Rising global infertility rates, changing reproductive health awareness, and strong. The rise in infertility rates, increased reproductive health awareness, and supportive government policies are still pushing forward growth in the infertility drugs market. According to WHO, around 48 million couples and 186 million individuals have been affected by infertility throughout the world, whereas according to CDC, 12% of women aged 15 to 44 in America suffer from infertility. Late pregnancies, exposure to the environment, and change in lifestyles are still causing decreased fertility rates, while the growth of fertility clinics along with the incorporation of advanced assisted reproductive technology like IVF in the presence of 489 fertility clinics and ART centers in the US only is still improving results and market acceptance.

Government programs continue to actively expand access to prescription infertility drugs through increased insurance coverage for assisted reproductive technology and fertility medications In April 2022, Japan's Ministry of Health, Labor and Welfare implemented a policy that subsidizes 70% of the cost of fertility treatments, while the UK's National Health Service is still providing access to fertility drugs that are necessary for fertility treatments.

Market Size and Forecast

• Market Size in 2026E: USD 4.47 Billion

• Market Size by 2035: USD 7.58 Billion

• CAGR: 6.03% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

To Get More Information On Infertility Drugs Market - Request Free Sample Report

Infertility Drugs Market Trends

• Pharmaceutical companies are developing next-generation gonadotropin formulations to improve treatment effectiveness while reducing the risk of ovarian hyperstimulation syndrome.

• Combination therapies using oral and injectable fertility drugs are gaining adoption to enhance ovarian stimulation, embryo implantation, and IVF success rates.

• Artificial intelligence is increasingly supporting personalized infertility treatment by optimizing hormone therapy selection and predicting reproductive outcomes.

• Online pharmacies are expanding fertility drug distribution through telemedicine integration, improving patient convenience, accessibility, and prescription management.

• Ongoing stem cell and regenerative medicine research is creating new opportunities for innovative infertility treatments, particularly for male reproductive disorders.

The U.S. Infertility Drugs Market Outlook

The U.S. infertility drugs market was valued at approximately USD 1.28 Billion in 2025 and is expected to reach approximately USD 2.28 Billion by 2035, growing at a CAGR of approximately 5.92%.

North America’s share in infertility drugs market in 2025 belongs to the US, which comprises 78% of the market owing to the presence of an extensive healthcare framework, large number of fertility clinics consisting of 489 ART centers across the nation, and proper government regulation providing health insurance to patients undergoing assisted reproductive technology and fertility hormones. Increasing investments in research & development further fuel the requirement for infertility drugs in the market. CDC estimation of ART usage and infertility incidence keeps on emphasizing US’s prominent role in this domain.

On April 29, 2024, Ferring Pharmaceuticals reported favorable findings from its BEYOND study, demonstrating the safety and efficacy of follitropin delta (Rekovelle) in women undergoing IVF under a GnRH agonist protocol. According to clinical studies, recombinant follitropins are highly effective in lowering the chances of developing ovarian hyperstimulation syndrome, a major complication associated with IVF, illustrating the ongoing pharmaceutical advancements aimed at increasing safety.

Infertility Drugs Market Segment Analysis

• By Drug Class, the gonadotropins segment dominated the infertility drugs market with a 39% revenue share in 2025, and is expected to see the highest growth.

• By Distribution Channel, the hospital pharmacies segment dominated the infertility drugs market with a 53% revenue share in 2025, while the online pharmacy segment is the fastest growing with a CAGR of approximately 6.63%.

• By Route of Administration, the oral segment dominated the infertility drugs market with a 46.8% revenue share in 2025, while the transdermal / intranasal segment is the fastest growing with a CAGR of approximately 7.4% during the forecast period.

• By End-User, the women segment dominated the infertility drugs market with a 73% revenue share in 2025, and is projected to witness the fastest growth.

By Drug Class, gonadotropins lead the market and are expected to grow fastest

The percentage market share of gonadotropins was estimated to be 39% in 2025. This drug group, which includes recombinant FSH and hCG, is an essential treatment for infertile men and women as these drugs help in stimulating ovulation and hormonal therapy, especially during ART and IVF treatment cycles, with a very high degree of efficacy in dealing with different fertility problems.

Regulatory approvals from bodies including the FDA and EMA continue to ensure the effectiveness and safety of new infertility treatment drugs within this class, while an expanding pipeline of IVF medications and male infertility pharmaceuticals, including stem cell-based fertility hormone therapy pioneered within Chinese fertility clinics, continues to broaden treatment options. Integration of AI-driven reproductive prediction tools and recombinant hormone treatments continues to customize treatment protocols for improved patient outcomes within this segment.

By Distribution Channel, hospital pharmacies dominate, online pharmacies grow fastest

The infertility drugs were predominantly distributed through hospital pharmacies and this was responsible for their share of 53% in the global market in 2025, which is the highest among all the distribution channels used for their distribution because of their easy accessibility, safety, and strong connection with the centers of ART and fertility clinics.

The online pharmacy category is gaining prominence as an essential growth catalyst, expected to grow at a CAGR of approximately 6.63% especially for patients living in rural areas or requiring discretion when using reproductive drugs. The advent of online healthcare websites and integration of telemedicine in fertility clinics has been aiding easy accessibility of prescribed infertility drugs, which in turn facilitates fast growth in this distribution channel.

By End-User, women dominate and grows fastest

The women segment accounted for 73% of the infertility drugs market in 2025, the largest end-user share, reflecting that female infertility affects approximately 12% of U.S. women between the ages of 15 and 44 and generates substantial demand for ovulation induction pharmaceuticals and female infertility drugs. Fertility guidance and fertility testing represent among the most frequently utilized treatments preceding pharmaceutical intervention.

Females with various disorders such as polycystic ovary syndrome (PCOS) and endometriosis usually need to be put on more advanced hormonal therapies that include fertility hormones as well as IVF drugs. The growing use of assisted reproductive technology and IVF by females is further boosting the demand for prescription infertility drugs suitable for women, and hence keeping this market segment as the leading one.

Regional Analysis

North America Infertility Drugs Market Insights

North America dominated the infertility drugs market in 2025, with a 39% share, with the U.S. infertility drugs market accounting for 78% of the region's total revenue. Advanced medical facilities, an abundance of fertility centers with 489 ART centers in the United States, and strict government control over health insurance that covers assisted reproductive technology and fertility hormone therapy contribute to the success of this region.

CDC projections of ART usage and infertility prevalence serve to continuously highlight the area’s strength in reproductive health treatments. Canada makes up a lesser but steady proportion of the regional demand for treatments, thanks to its own health system and increasing fertility treatment programs.

Get Customized Report as Per Your Business Requirement - Enquiry Now

Europe Infertility Drugs Market Insights

Europe held a significant infertility drugs market share, with strong demand across Germany, France, and the United Kingdom. Government schemes promoting increased access and availability of treatments, like Germany's backing of biosimilar infertility treatment drugs and fertility drugs' coverage by the NHS in the UK, continue to aid in regional market growth.

Higher regulations in EU for safer and alternate female infertility medicines will keep on driving the growth of female infertility medicines market and help the overall IVF medicines market. Germany is the major regional market due to its high manufacturing and health care coverage.

Asia Pacific Infertility Drugs Market Insights

Asia Pacific is the fastest-growing region, with a projected CAGR of 6.53% during the forecast period, driven by rising infertility rates, growing medical tourism, and expanding government backing for fertility treatment access. The move by Japan to finance 70% of fertility treatment costs and the position of India as the major producer of inexpensive infertility treatment drugs have greatly improved accessibility to modern reproductive care in the region.

The Chinese fertility clinics are constantly researching on stem cell therapy for male infertility which involves the use of fertility hormones. Increasing investments in health facilities and growing number of fertility clinics is contributing to the fast-growing region.

MEA & Latin America Infertility Drugs Market Insights

The Middle East, Africa, and Latin America are experiencing moderate growth in infertility drugs adoption, driven by expansion of assisted reproductive technology facilities and rising government support for reproductive health across both regions. Saudi Arabia leads regional demand in the Middle East, supported by expanding fertility clinic infrastructure and healthcare modernization initiatives.

Brazil is leading the demand from Latin America, backed by the rising number of fertility clinics as well as insurance cover for reproduction treatments. While there are still access issues in some countries, increasing awareness and investments are likely to help facilitate the growth of both regions in the infertility drugs market.

Market Dynamics

Growth Drivers: Drug innovation and updated safety policies transform treatment standards

The recent innovations in the infertility drug market have been largely oriented towards increasing the effectiveness and safety of the treatments, with regulatory authorities now demanding substantial clinical proof for new treatments. The April 2024 BEYOND study outcome of Ferring Pharmaceuticals that has highlighted the safety and effectiveness of follitropin delta in women going through IVF under the GnRH agonist treatment method is a case in point.

A new combination drug regimen has been introduced by Merck & Co., which consists of an oral hormonal drug and an injection drug for increasing the receptivity of the endometrium as well as ovulation, and this is in line with the overall trend of strategic alliances and collaborations in the field of reproductive medicine. The new guidelines published by the American Society for Reproductive Medicine in 2024, in response to possible risks of the treatments in the long run, keep on shaping patient management and treatment protocols.

Restraints: Insurance coverage gaps and treatment costs limit patient access

High costs of infertility treatment and lack of health insurance continue to pose major challenges for many infertile patients. According to the Department of Health and Human Services in the United States, on average, the patients undergo 2.5 treatment cycles to conceive, with one in vitro fertilization process estimated at about USD 15,000 to USD 30,000, while only 19 states in the United States offer insurance cover for infertility treatment by 2024.

People belonging to the poorer classes and in regions where there is no coverage mandate face a larger portion of the financial burden, creating considerable differences in the accessibility of treatment options. The tendency of fertility clinics to congregate in the wealthier regions exacerbates the issue of accessing infertility services for the poorer people.

Opportunities: Personalized medicine and expanding treatment access create growth potential

Continued advancement toward personalized medicine, including AI-driven reproductive prediction tools and recombinant hormone treatments customized for individual patient protocols, presents substantial opportunity for infertility drug manufacturers positioned to develop differentiated treatment approaches. Growing government support for expanded insurance coverage, exemplified by policy shifts in Japan and continued NHS coverage in the UK, continues to widen the addressable patient population for prescription infertility medications.

As the methods of genomic screening, which contributed to increased implantation rates in 2024 by making preimplantation genetic testing more accurate, have evolved, there is additional room for companies that will produce diagnostic or therapeutic alternatives. With an increase in the awareness about infertility globally and establishment of regulatory processes for new drugs, manufacturers who will be able to tackle the existing challenges can benefit significantly.

Recent Developments:

• 2024: In February 2024, Lupin introduced a prefilled, single-dose syringe called Ganirelix Acetate Injection to prevent early LH surges in women undergoing ovarian stimulation.

• 2024: In April 2024, Ferring Pharmaceuticals reported favorable findings from its BEYOND study, demonstrating the safety and efficacy of follitropin delta (Rekovelle) in women undergoing IVF under a GnRH agonist protocol.

• 2024: Throughout 2024, advances in genomic screening improved implantation success rates by increasing the accuracy of preimplantation genetic testing, enabling more reliable diagnosis of genetic issues in embryos.

Infertility Drugs Market key players are:

• Teva Pharmaceutical Industries Ltd.

• Merck KGaA

• Ferring B.V.

• Bayer AG

• Livzon Pharmaceutical Group Inc.

• Mankind Pharma Limited

• Sanofi S.A.

• Pfizer Inc.

• IBSA Institut Biochimique SA

• Organon & Co.

• Fuji Pharma Co., Ltd.

• Cipla Limited

• Sun Pharmaceutical Industries Ltd.

• Dr. Reddy's Laboratories Ltd.

• Lupin Limited

• Gedeon Richter Plc.

• Besins Healthcare

• Theramex

• Laboratoire CCD

• Genea Biomedx

Infertility Drugs Market Report Scope: